This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, AADI, EGRX, PYRGF, and TAOXShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Synaptogenix (TAOX). Anchiano Therapeutics vs. Its Competitors Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals PyroGenesis Canada Synaptogenix Virios Therapeutics (NASDAQ:VIRI) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Which has stronger valuation & earnings, VIRI or ANCN? Virios Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-17.82Anchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.90 Which has more volatility & risk, VIRI or ANCN? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Is VIRI or ANCN more profitable? Anchiano Therapeutics' return on equity of 36.08% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Anchiano Therapeutics N/A 36.08%27.40% Does the media prefer VIRI or ANCN? In the previous week, Virios Therapeutics had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Anchiano Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral Anchiano Therapeutics Neutral Do analysts recommend VIRI or ANCN? Virios Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 3.95%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Virios Therapeutics is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in VIRI or ANCN? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryVirios Therapeutics beats Anchiano Therapeutics on 8 of the 11 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.00M$842.24M$5.74B$9.79BDividend YieldN/A4.84%6.66%4.48%P/E Ratio20.671.1482.4126.45Price / SalesN/A26.88524.84106.22Price / CashN/A19.5625.7028.92Price / Book1.546.5610.626.54Net Income-$27.12M-$5.07M$3.28B$266.04M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$3.10-1.3%N/A+55.4%$23.00MN/A20.6716VIRIVirios Therapeutics0.1105 of 5 stars$5.06+2.3%$5.00-1.2%+2,456.7%$97.45MN/A-18.745WHWKWhitehawk TherapeuticsN/A$1.81+6.5%N/AN/A$80.12M$21.60M-30.1740News CoveragePositive NewsOSTXOS Therapies2.0897 of 5 stars$2.33+6.4%$18.00+672.5%-46.1%$74.31MN/A-2.95N/ANews CoverageAnalyst ForecastGap DownELYMEliem TherapeuticsN/A$2.48+4.2%N/A-68.1%$73.79MN/A-4.689Gap UpHigh Trading VolumeATNMActinium Pharmaceuticals1.893 of 5 stars$1.78-0.6%$4.50+152.8%-13.1%$55.53MN/A-1.2830News CoverageShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.70-2.3%N/A-0.3%$41.99M$25.07M-0.7540EGRXEagle Pharmaceuticals1.7677 of 5 stars$3.19flatN/A-39.8%$41.43M$257.55M0.00100Gap DownPYRGFPyroGenesis Canada0.1461 of 5 stars$0.22+2.4%N/A-64.6%$41.33M$9.14M-3.6790Negative NewsShort Interest ↑TAOXSynaptogenixN/A$6.96-0.7%N/AN/A$24.45M$3.96K-0.354Positive NewsGap Down Related Companies and Tools Related Companies VIRI Alternatives WHWK Alternatives OSTX Alternatives ELYM Alternatives ATNM Alternatives NBRV Alternatives AADI Alternatives EGRX Alternatives PYRGF Alternatives TAOX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
